Insight Molecular Diagnostics vs Scinai Immunotherapeutics
IMDX and SCNI side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How IMDX and SCNI compare
Scinai Immunotherapeutics grew revenue faster over the last twelve months (99.2% versus −60.8% for Insight Molecular Diagnostics).
Scinai Immunotherapeutics keeps more of each dollar of sales as profit, with a net margin of −634% compared with −2956% at Insight Molecular Diagnostics.
Insight Molecular Diagnostics scores higher on the StockData Score (7 against 6 for Scinai Immunotherapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | IMDX | SCNI |
|---|---|---|
| Size and price | ||
| Market cap | $58.2M | – |
| Share price | $1.78 | $0.372 |
| Change, 1 year | −75.9% | −96.2% |
| Change, 5 years | −96.3% | −100.0% |
| Beta (5Y) | 2.66 | 1.20 |
| Employees | 58 | 45 |
| StockData Score | ||
| Total score | 7 (better) | 6 |
| Valuation score | 0 | 0 |
| Growth score | 1 | 1 |
| Performance score | 1 (better) | 0 |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 34.9× | – |
| FCF yield | −53.2% | – |
| Growth | ||
| Revenue growth (TTM) | −60.8% | 99.2% (better) |
| Revenue growth, 5Y average | 27.2% | – |
| Net income growth (TTM) | – | −273% |
| Profitability | ||
| Gross margin | 48.3% (better) | −202% |
| Operating margin | −3012% | −575% (better) |
| Net margin | −2956% | −634% (better) |
| FCF margin | −1856% | −462% (better) |
| Return on equity | – | −84.8% |
| Return on invested capital | – | −74.7% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Current ratio | 2.00 (better) | 1.56 |
| Altman Z-score | −24.27 | – |
| Piotroski F-score | 4 (better) | 3 |
| Dividends and buybacks | ||
| Buyback yield | −44.7% | – |
| Shareholder yield | −44.7% | – |
| Ownership | ||
| Held by institutions | 56.4% | – |
| Held by insiders | 81.6% | 7.4% |
| Insider net buying, 12 months | $5.7M | – |
| Short interest, % of float | 17.0% | – |
Go deeper
- IMDX stock overview
- IMDX income statement
- IMDX valuation and score
- SCNI stock overview
- SCNI income statement
- SCNI valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.